Table 2.

TCGA database PRAD patient baseline data table.

Characteristics	Low expression of SLC45A2	High expression of SLC45A2	P value
n	157	140
Age, n (%)			0.176
< = 60	64 (21.5%)	68 (22.9%)
> 60	93 (31.3%)	72 (24.2%)
Pathologic T stage, n (%)			0.040
T2	98 (33%)	4 (1.3%)
T3	55 (18.5%)	85 (28.6%)
T4	4 (1.3%)	51 (17.2%)
Pathologic N stage, n (%)			0.048
N0	129 (43.4%)	27 (9.1%)
N1	28 (9.4%)	113 (38%)
Clinical T stage, n (%)			0.024
T1	71 (23.9%)	20 (6.7%)
T2	65 (21.9%)	1 (0.3%)
T3	21 (7.1%)	45 (15.2%)
T4	0 (0%)	74 (24.9%)
Clinical M stage, n (%)			0.029
M0	155 (52.2%)	0 (0%)
M1	2 (0.7%)	140 (47.1%)
Primary therapy outcome, n (%)			0.018
PD	14 (4.7%)	113 (38%)
SD	11 (3.7%)	12 (4%)
PR	17 (5.7%)	5 (1.7%)
CR	115 (38.7%)	10 (3.4%)
OS event, n (%)			0.006
Alive	153 (51.5%)	2 (0.7%)
Dead	4 (1.3%)	138 (46.5%)
DSS event, n (%)			0.697
No	154 (51.9%)	139 (46.8%)
Yes	3 (1%)	1 (0.3%)
PFI event, n (%)			0.423
No	126 (42.4%)	107 (36%)
Yes	31 (10.4%)	33 (11.1%)